A phase II study of FOLFOXIRI with bevacizumab in untreated metastatic colorectal cancer patients: A UGT1A1 genotype and safety results (QUATTRO study)

Takeshi Kato, Takayuki Yoshino, Kei Muro, Kentaro Yamazaki, Tatsuro Yamaguchi, Eiji Oki, Shigeyoshi Iwamoto, Akihito Tsuji, Goro Nakayama, Yasunori Emi, Tetsuo Touyama, Masato Nakamura, Masahito Kotaka, Hideaki Bando, Yoshinori Kagawa, Hiroya Taniguchi, Takeharu Yamanaka, Akiyoshi Kanazawa

Research output: Contribution to journalArticle

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)iii9-iii10
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume28
DOIs
Publication statusPublished - Jun 1 2017

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Kato, T., Yoshino, T., Muro, K., Yamazaki, K., Yamaguchi, T., Oki, E., Iwamoto, S., Tsuji, A., Nakayama, G., Emi, Y., Touyama, T., Nakamura, M., Kotaka, M., Bando, H., Kagawa, Y., Taniguchi, H., Yamanaka, T., & Kanazawa, A. (2017). A phase II study of FOLFOXIRI with bevacizumab in untreated metastatic colorectal cancer patients: A UGT1A1 genotype and safety results (QUATTRO study). Annals of oncology : official journal of the European Society for Medical Oncology, 28, iii9-iii10. https://doi.org/10.1093/annonc/mdx263.023